OGN
Europe says yes
Organon and Shanghai Henlius Biotech just got the European Commission’s approval for POHERDY, a pertuzumab biosimilar. In plain English: it’s the first and only approved pertuzumab biosimilar in Europe, which is kind of like getting the first invite to a party where everyone else is still stuck outside in the rain.
Why investors should care
This isn’t just regulatory paperwork with fancy letterhead. Biosimilars are a volume game, and being first matters because it can help a company grab market share before the room gets crowded.
For Organon, the win could mean:
- a fresh revenue stream in Europe
- a stronger biosimilars portfolio
- more leverage in a category where cheaper copies can still be very lucrative
The bigger picture
Organon has been trying to build itself into more than just a legacy healthcare name, and moves like this are part of that makeover. If POHERDY gets traction, it could help the company show investors there’s life beyond the usual patent-expiry treadmill.
Big picture: in pharma, being first to the finish line can matter almost as much as the finish line itself.